Leslie Muldoon

Associate Professor

Oregon Health & Science University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Purpose: Cisplatin-induced hearing loss (CIHL) is common and permanent. As compared with earlier otoprotectants, we hypothesized N-acetylcysteine (NAC) offers potential for stronger otoprotection through stimulation of glutathione (GSH) production. This study tested the optimal dose, safety, and efficacy of NAC to prevent CIHL. Patients and Methods: In this nonrandomized, controlled phase Ia/Ib trial, children and adolescents newly diagnosed with nonmetastatic, cisplatin-treated tumors received NAC intravenously 4 hours post-cisplatin. The trial performed dose-escalation across three dose levels to establish a safe dose that exceeded the targeted peak serum NAC concentration of 1.5 mmol/L (as identified from preclinical models). Patients with metastatic disease or who were otherwise ineligible were enrolled in an observation-only/control arm. To evaluate efficacy, serial age-appropriate audiology assessments were performed. Integrated biology examined genes involved in GSH metabolism and post-NAC GSH concentrations. Results: Of 52 patients enrolled, 24 received NAC and 28 were in the control arm. The maximum tolerated dose was not reached; analysis of peak NAC concentration identified 450 mg/kg as the recommended phase II dose (RP2D). Infusion-related reactions were common. No severe adverse events occurred. Compared with the control arm, NAC decreased likelihood of CIHL at the end of cisplatin therapy [OR, 0.13; 95% confidence interval (CI), 0.021–0.847; P = 0.033] and recommendations for hearing intervention at end of study (OR, 0.082; 95% CI, 0.011–0.60; P = 0.014). NAC increased GSH; GSTP1 influenced risk for CIHL and NAC otoprotection. Conclusions: NAC was safe at the RP2D, with strong evidence for efficacy to prevent CIHL, warranting further development as a next-generation otoprotectant.

Year:

2025

Purpose: Cisplatin-induced hearing loss (CIHL) is common and permanent. As compared to earlier otoprotectants, we hypothesized N-acetylcysteine (NAC) offers potential for stronger otoprotection through stimulation of glutathione production. This study tested the optimal dose, safety, and efficacy of NAC to prevent CIHL. Patients and Methods: In this nonrandomized, controlled Phase 1a/1b trial, children and adolescents newly diagnosed with non-metastatic, cisplatin-treated tumors received NAC intravenously four hours post-cisplatin. The trial performed dose-escalation across three dose levels to establish a safe dose that exceeded the targeted peak serum NAC concentration of 1.5 mM (as identified from preclinical models). Patients with metastatic disease or otherwise ineligible were enrolled in an observation-only/control arm. To evaluate efficacy, serial age-appropriate audiology assessments were performed. Integrated biology examined genes involved in glutathione metabolism and post-NAC glutathione concentrations. Results: Of 52 patients enrolled, 24 received NAC and 28 were in the control arm. The maximum tolerated dose was not reached; analysis of peak [NAC] identified 450 mg/kg as the recommended Phase 2 dose (RP2D). Infusion-related reactions were common. No severe adverse events occurred. Compared to the control arm, NAC decreased likelihood of CIHL at end of cisplatin therapy (odds ratio [OR] 0.13, 95% confidence interval [CI] 0.021-0.847, p=0.033) and recommendations for hearing intervention at end of study (OR 0.082, 95%CI 0.011-0.60, p=0.014). NAC increased glutathione; GSTP1 influenced risk for CIHL and NAC otoprotection. Conclusion: NAC was safe at the RP2D with strong evidence for efficacy to prevent CIHL, warranting further development as a next-generation otoprotectant. Trial number: NCT02094625

Year:

2024

Background MRI with gadolinium (Gd)-contrast agents is used to assess glioblastoma treatment response but does not specifically reveal heterogeneous biology or immune microenvironmental composition. Ferumoxytol (Fe) contrast is an iron nanoparticle that localizes glioblastoma macrophages and microglia. Therefore, we hypothesized that the use of Fe contrast improves upon standard Gd-based T1-weighted and T2/FLAIR analysis by specifically delineating immune processes. Methods In this, HIPAA-compliant institutional review board-approved prospective study, stereotactic biopsy samples were acquired from patients with treatment-naïve and recurrent glioblastoma based on MR imaging phenotypes; Gd and Fe T1 enhancement (Gd+, Fe+) or not (Gd–, Fe–), as well as T2-Flair hyperintensity (FLAIR+, FLAIR–). Analysis of genetic expression was performed with RNA microarrays. Imaging and genomic expression patterns were compared using false discovery rate statistics. Results MR imaging phenotypes defined a variety of immune pathways and Hallmark gene sets. Gene set enrichment analysis demonstrated that Gd+, Fe+, and FLAIR+ features were individually correlated with the same 7 immune process gene sets. Fe+ tissue showed the greatest degree of immune Hallmark gene sets compared to Gd+ or Flair+ tissues and had statistically elevated M2 polarized macrophages, among others. Importantly, the FLAIR+ Gd+ and Fe– imaging phenotypes did not demonstrate expression of immune Hallmark gene sets. Conclusions Our study demonstrates the potential of Fe and Gd-enhanced MRI phenotypes to reveal spatially distinct immune processes within glioblastoma. Fe improves upon the standard of care Gd enhancement by specifically localizing glioblastoma-associated inflammatory processes, providing valuable insights into tumor biology.

Year:

2023

Collaborators (9)

Etan Orgel

Professor of Clinical Pediatrics

University of Southern California

UNITED STATES
View details

Yueh-Yun Chi

Research Professor

University of Southern California

UNITED STATES
View details

Prakash Ambady

Oregon Health & Science University

UNITED STATES
View details

Ramon F Barajas

Oregon Health & Science University

UNITED STATES
View details

Michael N. Neely

Professor of Pediatrics

University of Southern California

UNITED STATES
View details

Colin Ross

Professor

The University of British Columbia

CANADA
View details

David R. Freyer

-

UNITED STATES
View details

Edward A Neuwelt

Oregon Health & Science University

UNITED STATES
View details

Laurie Eisenberg

University of Southern California

UNITED STATES
View details